Ginkgo Bioworks Holdings, Inc. is a synthetic biology platform company that sells biological R&D services and tools rather than finished end products. It operates two businesses: cell engineering, which helps customers design and optimize organisms and biological processes, and biosecurity, which provides biomonitoring and bioinformatics services to detect and track biological threats.
−150,6 %
−183,8 %
−25,1 %
4.92
4.92
| % | |
|---|---|
| Cell engineering services | 70% Custom biological R&D programs that help customers design, test, and optimize engineered cells. |
| Cell engineering tools | 15% Hardware, software, and related services sold to customers running more of their own R&D. |
| Biosecurity services | 15% Biomonitoring, sequencing, and bioinformatics services for government and commercial surveillance programs. |
Ginkgo sells mainly to enterprise, government, and research customers that need specialized biology capabilities they...
Buy cell engineering services and tools to accelerate discovery, develop biologics, and improve developability workflows.
Buy biosecurity services and strategic R&D support for surveillance, preparedness, and national-interest programs.
Buy engineering programs to improve manufacturing processes, product performance, and environmental outcomes.
Buy engineered biology programs aimed at sustainability, resilience, and food-system improvements.
Buy biomonitoring, sequencing, and reporting services for operational surveillance and risk management.
Ginkgo is headquartered in the United States and generates meaningful revenue from domestic customers, especially in...
Ginkgo is shifting from broad, end-to-end R&D collaborations toward a more flexible platform model that includes...
Tools reduce the upfront commitment required from customers and make Ginkgo easier to integrate into existing R&D organizations.
Biosecurity can diversify revenue beyond cell engineering if Ginkgo can win recurring surveillance and analytics programs.
Management is prioritizing higher-conviction programs and reducing reliance on structures that created volatile non-cash revenue.
Ginkgo remains exposed to customer concentration, uneven commercialization outcomes, and the challenge of proving that...
A small number of customers account for a meaningful share of revenue, so losing one can materially reduce sales and reputation.
Biosecurity growth relies on government, private, and multilateral funding, which can change with budgets and policy priorities.
Many customer programs are early-stage, so expected milestones, royalties, or follow-on work may never materialize.
The platform depends on specialized lab infrastructure, third-party suppliers, and technical execution at scale.
Ethical or legal concerns about GMOs can slow adoption and limit end-market growth.
MBIO · Pharmaceutical Preparations
WGS · Services-Health Services
BGLC · Services-Medical Laboratories
BioNexus Gene Lab Corp is a U.S.-listed holding company with operating subsidiaries in Malaysia that combines genomic screening services with industrial chemical trading.
INKT · Biological Products, (No Diagnostic Substances)
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
ZYME · Pharmaceutical Preparations
LNAI · Pharmaceutical Preparations
: 28/04/2026